2024-03-12
Hangzhou, China, March 5, 2024—The 18th World Congress of Anesthesiologists (WCA), organized by the World Federation of Societies of Anesthesiologists (WFSA), was held in Singapore from March 3rd to 7th, 2024. With delegates from more than 130 countries, the WCA is the only international congress offering a comprehensive program on global anesthesiology.
杭州，中国，2024年3月5日-2024年3月3日至7日第18届世界麻醉医师大会（World Congress of Anesthesiologists，WCA）在新加坡举行，会议由世界麻醉师学会（WFSA）主办。WCA 拥有来自 130 多个国家的代表，是唯一提供全球麻醉学综合计划的国际大会。
Professor Liu Jin from West China Hospital, Sichuan University, was invited to share his keynote report on “Anesthetic Drug Innovation and Development: Present and Future in China.” In his report, Professor Liu highlighted the encouraging phase III clinical data of Adamgammadex, which received an enthusiastic response from the audience.
WCA大会邀请四川大学华西医院刘进教授分享“Anesthetic Drug Innovation and Development: Present and Future in China”的主题报告。刘进教授在报告中特别介绍了中国自主研发的创新药奥美克松钠的研究进展，现场反响热烈。
Adamgammadex (Aom0498) is the next generation of specific neuromuscular blockade antagonists and has been shown to rapidly reverse neuromuscular blockades induced by rocuronium at various depths within 3 minutes. Compared to Sugammadex, Adamgammadex has a lower incidence of severe adverse reactions, such as allergic reactions, neuromuscular blockade recurrence, bradycardia, and laryngospasm, while maintaining more stable efficacy.
奥美克松钠（Aom0498）是全球新一代的特异性靶向肌松拮抗剂（适应症为拮抗罗库溴铵诱导的神经肌肉阻滞）。可以在3分钟内快速逆转不同深度的神经肌肉阻滞作用。相较于舒更葡糖钠（sugammadex），奥美克松钠在过敏反应、神经肌肉阻滞复发、心动过缓、喉痉挛等“特别关注的不良反应”的发生率更低，同时具有更稳定的药效。
Adamgammadex has completed a Pre-NDA meeting with the Centre of Drug Evaluation (CDE) of China and an End of Phase II Meeting with the FDA of the United States. It will submit a new drug application in China in the second quarter of 2024 and will be codeveloped and copromoted with our partner globally in the future.
奥美克松钠已经完成了与中国CDE的Pre-NDA沟通交流会和与FDA的End of Phase II Meeting，将在中国递交新药上市注册申请，未来也将携手合作伙伴共同走向国际。
About Aomo
Aomo Pharma, Inc. (the US branch of Adamerck), is dedicated to the research of innovative drugs with independent intellectual property rights that are urgently needed globally. Adhering to the corporate mission of "Better Drugs for Better Lives", we have devoted more than two decades to the research and development of new drugs. Currently, our company boasts a pipeline of more than ten innovative drugs with independent intellectual property rights. These products span various application fields, such as anesthesia, cardiovascular and cerebrovascular surgery, and ophthalmology. We are engaged in the commercial development of these products on a global scale, and they hold significant clinical value and broad market prospects. Among these, Aom0498 has entered the Pre-NDA phase and is expected to become the only patented drug globally in the muscle relaxation antagonist field. Aom0499, Aom0319, and Aom0315 have all entered clinical studies at both the international and national levels, with pipeline advancements in Phases I to III. Our company continues to embrace the philosophy of innovative development, focusing on the innovative design of drugs and the industrialization of new drug development as our core competitive strengths. We are committed to continuously promoting the research, development, and market launch of new drugs with independent intellectual property rights, aspiring to become a global leader in the pharmaceutical industry within our specialized fields.
BioToChina.org 